The corpus-predominant gastritis index may serve as an early marker of helicobacter pylori-infected patients at risk of gastric cancer

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 10, 2013, Pages 969-978

  Tsai, Y C ^a,b   Hsiao, W H ^a   Yang, H B ^a,c   Cheng, H C ^a   Chang, W L ^a   Lu, C C ^b   Sheu, B S ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Tainan Hospital   (Taiwan)

^c Ton Yen General Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORPUS PREDOMINANT GASTRITIS INDEX; DISEASE MARKER; DISEASE SEVERITY; DUODENUM ULCER; FEMALE; FIRST DEGREE RELATIVE; HELICOBACTER INFECTION; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; OPERATIVE LINK ON GASTRIC INTESTINAL METAPLASIA ASSESSMENT; OPERATIVE LINK ON GASTRITIS ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STOMACH ATROPHY; STOMACH CANCER; VALIDITY;

ADENOCARCINOMA; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL MUCOSA; MALE; METAPLASIA; MIDDLE AGED; PEDIGREE; PEPTIDES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS;

EID: 84876498649     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12291     Document Type: Article

References (34)

1. WHO. Schistosomes, liver flukes and Helicobacter pylori: IRAC working group on the evaluation of carcinogenic risks to humans. IRAC monographs on the evaluation of carcinogenic risks to humans. IRAC scientific publ 1994; 61: 218-20.
2. Parsonnet J, Friedman GD, Vandersteen DP, et al,. Helicobacer pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
3. Correa P,. Human gastric carcinogenesis: a multistep and multifactorial process-first American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735-40.
4. Uemura N, Okamoto S, Yamamoto S, et al,. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
5. Correa P, Piazuelo MB,. The gastric precancerous cascade. J Dig Dis 2012; 13: 2-9.
6. Meining A, Stolte M, Hatz R, et al,. Differing degree and distribution of gastritis in Helicobacter pylori-associated diseases. Virchows Arch 1997; 431: 11-5.
7. Miehlke S, Hackelsberger A, Meining A, et al,. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998; 78: 263-6.
8. Miehlke S, Hackelsberger A, Meining A, et al,. Histological diagnosis of Helicbacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer 1997; 73: 837-9.
9. Hansson LE, Nyrén O, Hsing AW, et al,. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335: 242-9.
10. Rugge M, Genta RM, OLGA group. Staging gastritis: an international proposal. Gastroenterology 2005; 129: 1807-8.
11. Rugge M, Meggio A, Pennelli G, et al,. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-6.
12. Rugge M, de Boni M, Pennelli G, et al,. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104-11.
13. Satoh K, Osawa H, Yoshizawa M, et al,. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008; 13: 225-9.
14. Capelle LG, de Vries AC, Haringsma J, et al,. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-8.
15. Rugge M, Fassan M, Pizzi M, et al,. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011; 17: 4596-601.
16. Wong BC, Lam SK, Wong WM, et al,. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-94.
17. Brenner H, Bode G, Boeing H,. Helicabacter pylori infection among the offspring of patients with stomach cancer. Gastroenterology 2000; 118: 31-5.
18. El-Omar EM, Oien K, Murray LS, et al,. Increased prevalence of precancerous changes in relatives of gasstric cancer patients: critical role of Helicobacter pylori. Gastroenterology 2000; 118: 22-30.
19. Sheu BS, Yang HB, Sheu SM, Huang AH, Wu JJ,. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003; 9: 5245-51.
20. Marcos-Pinto R, Carneiro F, Dinis-Ribeiro M, et al,. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment Pharmacol Ther 2012; 35: 1451-9.
21. Wang TC, Goldenring JR, Dangler C, et al,. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 1998; 114: 675-89.
22. Weis VG, Goldenring JR,. Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 2009; 12: 189-97.
23. Nam KT, Lee HJ, Sousa JF, et al,. Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology 2010; 139: 2028-37.
24. Schmidt PH, Lee JR, Joshi V, et al,. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 1999; 79: 639-46.
25. Nomura S, Baxter T, Yamaguchi H, et al,. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology 2004; 127: 582-94.
26. Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR,. Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci 2002; 47: 573-8.
27. Yoshizawa N, Takenaka Y, Yamaguchi H, et al,. Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. Lab Invest 2007; 87: 1265-76.
28. Goldenring JR, Nam KT, Wang TC, Mills JC, Wright NA,. Spasmolytlic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010; 138: 2207-10.
29. Sheu BS, Sheu SM, Yang HB, Huang AH, Wu JJ,. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection. Gut 2003; 52: 927-32.
30. Sheu BS, Odenbreit S, Hung KH, et al,. Interaction between host gastric Sialyl-Lewis X and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis B antigen. Am J Gastroenterol 2006; 101: 36-44.
31. Chuang CH, Yang HB, Sheu SM, et al,. Helicobacter pylori with stronger intensity of CagA phosphorylation lead to an increased risk of gastric intestinal metaplasia and cancer. BMC Microbiol 2011; 11: 121-8.
32. Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY,. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009; 104: 1642-9.
33. Chang WL, Yang HB, Cheng HC, Chuang CH, Lu PJ, Sheu BS,. Increased gastric osteopontin expression by Helicobacter pylori infection can correlate with more severe gastric inflammation and intestinal metaplasia. Helicobacter 2011; 16: 217-24.
34. Dixon MF, Genta RM, Yardley JH, Correa P,. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.